Salmeterol, a long-acting bronchodilator used to manage asthma and chronic obstructive pulmonary disease (COPD), was developed in the 1980s and approved for medical use in the mid-1990s. Its history is marked by its effectiveness in providing prolonged bronchodilation and improving respiratory function, especially as part of combination therapy with inhaled corticosteroids. Salmeterol works by selectively stimulating β₂-adrenergic receptors in the airways, leading to smooth muscle relaxation and easier breathing. Its development emphasized extended-release formulations for sustained symptom control, and it has become a key component in the long-term management of asthma and COPD worldwide.
BRAND NAMES
Serevent – The primary brand name for salmeterol inhalers
Advair – Combination inhaler with fluticasone (corticosteroid)
Seretide – Combination inhaler available in some countries with fluticasone
AirFluSal – Combination product with fluticasone for asthma and COPD management
MECHANISM OF ACTION
Salmeterol is a long-acting β₂-adrenergic receptor agonist (LABA) that works by stimulating β₂ receptors in the smooth muscle of the airways. This activation triggers adenylate cyclase, increasing cyclic AMP (cAMP) levels, which in turn relaxes bronchial smooth muscle. The result is prolonged bronchodilation, easing airflow obstruction in patients with asthma or COPD. Salmeterol has a slow onset but a long duration of action (approximately 12 hours), making it suitable for maintenance therapy rather than acute symptom relief.
PHARMACOKINETICS
Absorption
When inhaled, salmeterol is mostly absorbed locally in the lungs to provide bronchodilation, with only a small amount entering systemic circulation. Any swallowed portion undergoes first-pass metabolism in the liver, minimizing systemic exposure and side effects.
Distribution
Salmeterol exhibits a large volume of distribution, indicating extensive tissue distribution. The central compartment volume is approximately 177 L, while the peripheral compartment volume is 3160 L. This high volume reflects its lipophilic nature and propensity to distribute into tissue rather than remaining in the plasma.
Metabolism
Salmeterol is mainly metabolized in the liver by the enzyme CYP3A4 into inactive compounds. This extensive metabolism helps keep systemic drug levels low while maintaining effective bronchodilation in the lungs.
Elimination
Salmeterol and its metabolites are primarily excreted in the feces via biliary secretion, with a smaller portion eliminated in the urine. The drug has a terminal half-life of approximately 5.5 hours after systemic absorption, but its bronchodilatory effects last up to 12 hours due to its strong affinity for β₂ receptors in the lungs.
PHARMACODYNAMICS
Salmeterol is a long-acting β₂-agonist that relaxes airway smooth muscle by increasing cAMP, leading to bronchodilation. It has a slow onset (10–20 min) but long duration (~12 hours), making it effective for maintenance therapy in asthma and COPD. It is not used for acute attacks and has minimal heart-related side effects due to β₂ selectivity.
ADMINISTRATION
Salmeterol is administered by inhalation using either a metered-dose inhaler (MDI) or a dry powder inhaler (DPI). The usual dose for adults and children over 4 years is 50 micrograms twice daily, about 12 hours apart. It is intended for regular maintenance therapy and should not be used for immediate relief of asthma attacks. Patients are advised to rinse their mouth after inhalation to prevent throat irritation or fungal infections and to use it consistently at the same times each day for optimal effect.
DOSAGE AND STRENGTH
Adults and children ≥4 years: 50 µg twice daily (every 12 hours) via inhalation.
Formulations/Strengths:
Metered-dose inhaler (MDI): 25 µg per actuation (usually 2 actuations per dose = 50 µg).
Dry powder inhaler (DPI, e.g., Diskus): 50 µg per inhalation.
Maximum recommended dose: Do not exceed 100 µg per day.
DRUG INTERACTIONS
Salmeterol may interact with β-blockers, other adrenergic drugs, MAO inhibitors, tricyclic antidepressants, CYP3A4 inhibitors, and certain diuretics, increasing the risk of reduced effectiveness or heart-related side effects.
FOOD INTERACTIONS
Salmeterol has no significant food interactions, as it is administered by inhalation and not absorbed through the gastrointestinal tract in meaningful amounts. Patients can take it with or without food.
CONTRAINDICATIONS
Salmeterol is contraindicated in patients with hypersensitivity to the drug, for acute asthma attacks, or if taking another LABA for asthma. Caution is needed in severe heart disease, hypertension, diabetes, or hyperthyroidism.
SIDE EFFECTS
Headache
Throat irritation
Cough
Tremors
Palpitations
OVER DOSE
Overdose may cause fast heartbeat, tremors, headache, nervousness, muscle cramps, and low potassium. Stop the drug and provide supportive care, monitoring heart and electrolytes.
TOXICITY
Salmeterol toxicity is rare but can occur with excessive use, leading to severe cardiovascular effectssuch as tachycardia, arrhythmias, and palpitations, as well as hypokalemia, tremors, and nervousness. Management involves discontinuing the drug, providing supportive care, and monitoring cardiac function and electrolytes.
